Edition:
United States

Prima BioMed Ltd (PRR.AX)

PRR.AX on Australia Stock Exchange

0.03AUD
10:09pm EDT
Change (% chg)

$0.00 (+0.00%)
Prev Close
$0.03
Open
$0.03
Day's High
$0.03
Day's Low
$0.03
Volume
94,862
Avg. Vol
1,395,334
52-wk High
$0.05
52-wk Low
$0.03

Latest Key Developments (Source: Significant Developments)

Prima BioMed announces data from IMP321 AIPAC clinical trial in breast cancer
Wednesday, 21 Dec 2016 04:33pm EST 

Prima BioMed Ltd : Prima BioMed Ltd - data demonstrated activation and an increased level of blood monocytes, dendritic cells and CD8 T-cells . Prima BioMed Ltd - IMP321 is safe and well tolerated . Prima BioMed Ltd - subject to confirmation of dose escalation committee on 30 Dec, Prima will now commence randomised phase of trial in January 2017 . Prima BioMed Ltd - patients will receive paclitaxel treatment plus placebo or paclitaxel in conjunction with imp321 .Prima BioMed announces data from IMP321 AIPAC clinical trial in breast cancer.  Full Article

Prima signs MOU with WuXi
Tuesday, 22 Nov 2016 08:15pm EST 

Prima Biomed Ltd - : WuXi & Prima sign MOU for strategic partnership .Mou was signed to form a strategic biologics development and manufacturing partnership.  Full Article

Prima signs MOU with WuXi
Tuesday, 22 Nov 2016 06:14pm EST 

Prima Biomed Ltd - : WuXi & Prima sign MOU for strategic partnership .Mou was signed to form a strategic biologics development and manufacturing partnership.  Full Article

Prima Biomed enters agreement with Sydys to advance CVac Program
Thursday, 12 May 2016 03:26am EDT 

Prima BioMed Ltd : PRR enters agreement with Sydys to Advance Cvac Program . In the spin out transaction Prima will receive a 9.9% equity stake in sydys at closing as consideration for the assets being transferred . Prima could receive over A$400 million for achievement of set commercial sales targets, in addition to single digit royalties on sales .  Full Article

Prima BioMed Ltd gains Belgian regulatory approval to commence IIB study of IMP321
Monday, 26 Oct 2015 08:44pm EDT 

Prima BioMed Ltd:Prima Biomed gains Belgian regulatory approval to commence a registration phase IIB study of imp321.Says imp321 phase IIB trial initiation is expected before the end of 2015.  Full Article

Prima BioMed announces investment from Nyenburg
Tuesday, 13 Oct 2015 01:38am EDT 

Prima BioMed Ltd:Has raised about A$1.55 mln via a placement of shares at A$0.05 per share to Nyenburgh Investment Partners (NYIP).The proceeds from the Placement will be used to fund Prima's IMP321 clinical trial program and provide additional working capital.  Full Article

Prima BioMed Ltd announces issue of shares
Tuesday, 23 Jun 2015 02:06am EDT 

Prima BioMed Ltd:Issues 5,000,000 ordinary shares.  Full Article

Prima BioMed Ltd announces issue of shares
Thursday, 11 Jun 2015 03:43am EDT 

Prima BioMed Ltd:Issues 1,266,500 ordinary shares.  Full Article

Prima Biomed Ltd announces ownership interest of JPMorgan Chase & Co and affiliates
Tuesday, 2 Jun 2015 05:23pm EDT 

Prima Biomed Ltd:Says that JPMorgan Chase & Co and its affiliates has an interest in 153,712,260 ordinary shares of the company, representing 8.92 pct. of total voting power.  Full Article

Prima BioMed Ltd announces issue of shares
Thursday, 28 May 2015 03:28am EDT 

Prima BioMed Ltd:Issues 5,000,000 fully paid ordinary shares.  Full Article

More From Around the Web

BRIEF-Prima signs MOU with WuXi

* Mou was signed to form a strategic biologics development and manufacturing partnership Source text for Eikon: Further company coverage: